Cannabinoid biotechnology company MediPen is launching its own dedicated 1,800-square-foot marijuana research facility this summer, which will also provide a platform for anyone looking to utilize its facilities for the purposes of driving innovation around the use of medicinal cannabis.
The company, which has had big success selling non-psychoactive CBD vaporizers that users claim to have a long list of medicinal benefits, is currently in the process of securing a license from the Home Office to import and work with controlled compounds found in cannabis so it can study the plant in greater detail.
RELATED: International Cannabis News
These include ?9-Tetrahydrocannabinol (THC), which will be studied in the laboratory with regard to cancer patients and with the aim of minimizing the negative impact of existing chemotherapy-based treatments such as nausea and vomiting through its antiemetic properties, along with attempting to suppress metastasis through inhibiting the proliferation of cancer cells.
